Dynavax and Vical Seek Blockbuster Status
The Bedford Report Provides Equity Research on Dynavax and Vical
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 07/26/11 -- There is plenty of optimism surrounding the biotechnology industry as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investment research on Dynavax Technologies Corporation (NASDAQ: DVAX) and Vical, Inc. (NASDAQ: VICL). Access to the full company reports can be found at:
Citing agency officials, The Wall Street Journal reported this month that the Food and Drug Administration (FDA) has approved 20 new drugs so far this year -- just one short of the total for all of 2010. Some lawmakers in Washington have been arguing that the FDA's tougher safety stance has slowed down the pace of drug approvals and is hurting the pharmaceutical and biotech industry.
Janet Woodcock, the head of the FDA's drug division, defended the FDA's role, saying challenges being faced by the biotech and pharmaceutical industry are related to high failure rates of drugs in the development process rather than FDA regulations.
A study released by BIO and BioMedTracker claims that the success rate in bringing new medicines to market in the past six years is only about half of what it had been previously. The study claims, however, that biotech drugs are twice as likely to gain approval, compared to more traditional chemical drugs.
The Bedford Report releases stock research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.
Dynavax Technologies is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The company's lead product candidate is "HEPLISAV," a Phase 3 investigational adult hepatitis B vaccine. Last week the company announced that its latest studies show HEPLISAV worked better than an older vaccine, GlaxoSmithKline's Engerix-B.
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Earlier this month the company said it has granted a global license to Japan's Astellas Pharma for its vaccine candidate TransVax.
The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at .
Contact:
The Bedford Report
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.07.2011 - 06:16 Uhr
Sprache: Deutsch
News-ID 1025007
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Commercial & Investment Banking
Anmerkungen:
Diese Pressemitteilung wurde bisher 145 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dynavax and Vical Seek Blockbuster Status
"
steht unter der journalistisch-redaktionellen Verantwortung von
The Bedford Report (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
